國家衛生研究院 NHRI:Item 3990099045/6970
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 925186      在线人数 : 902
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/6970


    题名: Front-line antibiotic therapy in early-stage H. Pylori-positive gastric Diffuse Large B-Cell Lymphomas with or without malt features
    作者: Chen, LT;Kuo, SH;Yeh, KH;Wu, MS;Lin, CW;Hsu, PN;Wang, HP;Cheng, AL
    贡献者: National Institute of Cancer Research
    摘要: Background :Our earlier study showed that certain proportion of early-stage H. pylori (HP)-positive gastric diffuse large B-cell lymphoma (DLBCL) with features of mucosa-associated lymphoid tissue (MALT), DLBCL(MALT), could achieve long-term complete pathological remission (pCR) after frontline HP eradication therapy (HPE). In this retrospective, explorative study, we evaluate the efficacy of HPE on early-stage gastric DLBCL without features of MALT, the pure (de novo) DLBCL, in comparison with its efficacy on high-grade transformed gastric MALT lymphoma, the DLBCL(MALT). Methods :A total of 50 patients of stage IE/IIE1, HP-positive gastric DLBCL with frontline HPE treatment were included. Of them, 16 patients with pure (de novo) DLBCL were retrospectively identified from medical/pathologic review and 34 patients with DLBCL (MALT) were an expanded cohort of one previously reported multicenter prospective study. pCR was defined as regression of DLBCL to Wotherspoon grade 2 or less in all histologic sections of follow-up endoscopic biopsies. Results: HP infection was successfully eradicated in 100% (16/16) of the pure (de novo) DLBCL and 94.1% (32/34) of the DLBCL(MALT) patients. A total of 68.8% (11/16) of pure (de novo) DLBCL and 56.3% (18/32) of DLBCL(MALT) patients achieved pCR after HPE. The median time-to-pCR was 2.1 months (95% CI, 0.6–3.7) for pure (de novo) DLBCL and 5.0 months (95% CI, 2.8–7.5) for DLBCL(MALT) (P = 0.024). At a median follow-up of 7.7 years (95% CI, 4.5–10.9), all patients with pCR after HPE were alive and free of lymphoma, except one patient with pure (de novo) DLBCL died of lung cancer. Conclusions: Similar to DLBCL(MALT), a substantial portion of early-stage, HP-positive gastric pure (de novo) DLBCL remains HP-dependent and responds to antibiotic treatment. Prospective studies to validate the findings are warranted.
    日期: 2012-10
    關聯: Annals of Oncology. 2012 Oct;23(Suppl. 11):105.
    Link to: http://dx.doi.org/10.1093/annonc/mds572
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0923-7534&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000310634300352
    显示于类别:[陳立宗] 會議論文/會議摘要

    文件中的档案:

    档案 描述 大小格式浏览次数
    ISI000310634300352.pdf53KbAdobe PDF476检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈